Is Biorestorative Therapies going out of business?

BIORESTORATIVE THERAPIES, INC. (BRTX) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

BIORESTORATIVE THERAPIES, INC. (BRTX) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 112.13% (YoY)

Five questions, kept separate

Survival - Critical

2-4 mo of estimated runway from 2026-03-31, based on $3.1M of cash and short-term investments against $10.9M of annual burn. Adjusted shares outstanding increased 112.1% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Balanced

39.5% net-cash backing support a balanced pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 112.13% (YoY)
• FCF margin: -3031.70%
• Cash Runway (years): 0.29y
• Revenue CAGR (3Y): 38.36%
• Revenue growth YoY: -7.32% (YoY)
• Return on Assets: -306.92%
• Cash Burn Deceleration: -29.11% QoQ improvement (Worsening)
• Price / Sales: 10.3x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• Operating leverage: -4658.9%
• Effective Tax Rate: 0.00% (loss-making)

Read from filings through 2026-05-14.

Price as of 2026-09-07.